ScholarLens Back to search
2013•Chinese Journal of New Drugs and Clinical RemediesRequires access

New strategy of treatment in tumor bone metastasis:denosumab

Qian Ju

Open publisher page 0 citations

Abstract

The discovery of osteoprotegerin(OPG) /receptor activator of nuclear factor kB(RANK) / receptor activator of nuclear factor kB ligand(RANKL) system promoted the development of RANKL monoclonal antibody denosumab.Denosumab could prevent the interaction of RANKL and its receptors,thus inhibiting osteoclast formation as well as its survival and function,reduce the bone absorption,increase the bone mineral density.In May 2010,the drug had been approved for use in postmenopausal osteoporosis and prostate cancer patients with hormone suppression treatment related bone loss in the European Union.Denosumab is a promising new method in treating bone tumors of dissolve osseous.

About this research paper

What this paper is about

The discovery of osteoprotegerin(OPG) /receptor activator of nuclear factor kB(RANK) / receptor activator of nuclear factor kB ligand(RANKL) system promoted the development of RANKL monoclonal antibody denosumab.Denosumab could prevent the interaction of RANKL and its receptors,thus inhibiting osteoclast formation as well as its survival and function,reduce the bone absorption,increase the bone mineral density.In May 2010,the drug had been approved for use in postmenopausal osteoporosis and prostate cancer patients with hormone suppression treatment related bone loss in the European Union.Denosumab is a promising new method in treating bone tumors of dissolve osseous.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The discovery of osteoprotegerin(OPG) /receptor activator of nuclear factor kB(RANK) / receptor activator of nuclear factor kB ligand(RANKL) system promoted the development of RANKL monoclonal antibody denosumab.Denosumab could prevent the interaction of RANKL and its receptors,thus inhibiting osteoclast formation as well as its survival and function,reduce the bone absorption,increase the bone mineral density.In May 2010,the drug had been approved for use in postmenopausal osteoporosis and prostate cancer patients with hormone suppression treatment related bone loss in the European Union.Denosumab is a promising new method in treating bone tumors of dissolve osseous.

Key concepts: Denosumab, RANKL, Osteoprotegerin, Bone metastasis, Bone mineral, Osteoclast, Prostate cancer, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
New strategy of treatment in tumor bone metastasis:denosumab — Research Paper | ScholarLens